Dreem 3S

Dreem 3S from Beacon Biosignals makes it easy to include sleep quality endpoints in biopharma clinical studies, helping to unlock new insights into sleep physiology.


The company works with biopharma companies, academic medical centers, and neurotechnology developers to improve the diagnosis and treatment of neurological and psychiatric diseases. The aim is to treat neurological and psychiatric diseases through its EEG analytics platform, which utilizes portal reporting, standardized neurobiomarkers and machine learning algorithms that “increase the probability of success at each stage of drug development.